ICBE-EMF Submits: Wireless Technology Not Adequately Assessed for Hazards to Human Health and Environment
New peer-reviewed paper presents scientific case for revision of limits TUCSON, Ariz., Oct. 18, 2022 /PRNewswire/ -- The International Commission on the Biological Effects of Electromagnetic Fields (ICBE-EMF) is challenging the safety of current wireless exposure limits to radiofrequency radiation (RFR) and is calling for an independent evaluation. Published today in the journal Environmental Health, "Scientific evidence invalidates health assumptions underlying...
TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM
OPALESCENCE Phase II feasibility study of TLX250-CDx in patients with triple-negative breast cancer – early results suggest potential to detect carbonic anhydrase IX (CAIX) expression, theranostic potential in this difficult to treat disease. PERTINENCE Early Phase I feasibility study of TLX250-CDx in patients with non-muscle-invasive bladder cancer, a collaboration with ATONCO...
GenScript ProBio Enters Strategic Collaboration with Hibiocy Co. Ltd, the affiliate of Rojukiss International Public Company Limited (KISS) – the leading Thai-based Beauty & Health company, for the development...
SINGAPORE, Oct. 17, 2022 /PRNewswire/ -- GenScript ProBio (a global one-stop CDMO from GenScript Group) today announced a strategic collaboration with Hibiocy Co. Ltd., a private corporation based in Bangkok, Thailand, to accelerate a respiratory-care medical device, COVITRAP™ which contains human antibody for Covid-19 inhibiting project. COVITRAP™ is a nasal spray which is...
Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia
Clinical trial assessing allogeneic, HLA-matched, donor-derived allogeneic CAR-T therapy SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Oct. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the...
PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022
DAEJEON, South Korea, Oct. 17, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, one of the Company's first immuno-oncology drug candidates, at SITC (Society for Immunotherapy of Cancer) Annual Meeting taking place November 8-12 in Boston. ...
Value of Tissue Analytics for Remote Care Highlighted in Research From Australian Virtual Wound Care Program
PITTSBURGH and SYDNEY, Oct. 17, 2022 /PRNewswire/ -- Net Health, a leading provider of specialty electronic health record (EHR) systems and advanced healthcare analytics, announced results from a first-of-its-kind study for a promising wound care treatment model. The findings showed Net Health® Tissue Analytics, the company's AI-powered wound imaging and analysis...
Eyenuk secures $26 Million Series A funding to accelerate global access to AI-powered eye-screening technology
Brings Eyenuk's total funding to over $43 million Funding round led by AXA IM Alts; joined by T&W Medica A/S, Kendall Capital Partners, and others Eyenuk adds three new board members Funding affirms Eyenuk's standing as the global leader among developers of autonomous AI solutions for ophthalmology LOS ANGELES, Oct....
Kira Pharmaceuticals to Present First-in-Human Clinical Data at American Society for Nephrology Kidney Week 2022
Phase 1 biomarker data confirms proof of mechanism with dose-dependent and potent inhibition of alternative and terminal pathways with KP104 via dual-targeting mechanism Data demonstrated KP104 was safe and well tolerated, and supports further investigation of KP104 in Phase 2 clinical studies CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Kira Pharmaceuticals,...
Collaboration Between Drug and Medical Food Manufacturers to Boost Market’s Growth
Frost & Sullivan says the prevalence of lifestyle diseases and geriatric population drives demand for medical food globally SAN ANTONIO, Oct. 17, 2022 /PRNewswire/ -- Frost & Sullivan's recent analysis, Global Medical Food Growth Opportunities, finds that the rising consumer awareness about the importance of nutrition in disease treatment and patients' recovery pushes medical food product formulators to launch...
Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market
New agreement adds two Telix investigational PET imaging radiotracers to GE Healthcare's immuno-diagnostic portfolio, to enable patient selection and monitoring in immunotherapy trials Telix tracers evaluate levels of carbonic anhydrase IX and lactate in tumours to inform and improve therapy selection GE Healthcare's Pharmaceutical Diagnostics business is an established global supplier...
